SCHEMBL1639404

SCHEMBL1639404

COc1ccccc1C(C)(O)c1cccc(-c2cccc(-c3ccccc3)c2OCc2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGAM O43451 3/20 0.44
GAA P10253 3/20 0.44
SI P14410 3/20 0.44
MGAM2 Q2M2H8 3/20 0.44
PTPN5 P54829 1/20 0.44
FFAR1 O14842 2/20 0.42
KDM4E B2RXH2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTGER1 P34995 5/20 0.41
PTGER4 P35408 4/20 0.40
PTGER3 P43115 4/20 0.40
PTGER2 P43116 4/20 0.40
ERN1 O75460 1/20 0.40
BCHE P06276 1/20 0.40
HTR7 P34969 2/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
FYN P06241 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637791 0.94 PTPN5 (0.42) MGAMGAASIMGAM2PTPN5
SCHEMBL1637529 0.93 PTPN5 (0.48) MGAMGAASIMGAM2PTPN5
SCHEMBL1638857 0.88 MGAM (0.46) MGAMGAASIMGAM2FFAR1
SCHEMBL1638726 0.87 PTPN5 (0.47) MGAMGAASIMGAM2PTPN5
SCHEMBL12765326 0.86 PTPN5 (0.41) GAAPTPN5FFAR1KDM4EL3MBTL1
SCHEMBL1637767 0.84 PTPN5 (0.48) MGAMGAASIMGAM2PTPN5
SCHEMBL27864181 0.83 MAOB (0.48) MGAMGAASIMGAM2FFAR1
SCHEMBL1638077 0.83 MGAM (0.44) MGAMGAASIMGAM2PTPN5
SCHEMBL1637643 0.81 BCHE (0.43) MGAMGAASIMGAM2KDM4E
SCHEMBL1638148 0.80 PTPN5 (0.47) MGAMGAASIMGAM2PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493932-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056423-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098429-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 MGAM 536/4885GAA 4064/4885SI 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.